IONS - Ionis late-stage rare disease data fails to impress Bernstein
2023-09-26 15:08:59 ET
More on Ionis Pharmaceuticals
- Ionis Pharmaceuticals: Mid-Sized Pharma Is A Strong Buy Opportunity For All-Comers
- Novartis and Ionis in pact for new cardiovascular therapy
- AstraZeneca-Ionis deal for eplontersen expands to Latin America
- Seeking Alpha's Quant Rating on Ionis Pharmaceuticals
For further details see:
Ionis late-stage rare disease data fails to impress Bernstein